AU2010298264B2 - Methods, compositions, and kits for reducing anti-antibody responses - Google Patents

Methods, compositions, and kits for reducing anti-antibody responses Download PDF

Info

Publication number
AU2010298264B2
AU2010298264B2 AU2010298264A AU2010298264A AU2010298264B2 AU 2010298264 B2 AU2010298264 B2 AU 2010298264B2 AU 2010298264 A AU2010298264 A AU 2010298264A AU 2010298264 A AU2010298264 A AU 2010298264A AU 2010298264 B2 AU2010298264 B2 AU 2010298264B2
Authority
AU
Australia
Prior art keywords
subject
allotypic
monoclonal antibody
human
abs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010298264A
Other languages
English (en)
Other versions
AU2010298264A1 (en
Inventor
John Simard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xbiotech Inc
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of AU2010298264A1 publication Critical patent/AU2010298264A1/en
Application granted granted Critical
Publication of AU2010298264B2 publication Critical patent/AU2010298264B2/en
Assigned to XBIOTECH INC. reassignment XBIOTECH INC. Request to Amend Deed and Register Assignors: XBIOTECH, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010298264A 2009-09-24 2010-09-23 Methods, compositions, and kits for reducing anti-antibody responses Active AU2010298264B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24530509P 2009-09-24 2009-09-24
US61/245,305 2009-09-24
PCT/US2010/049924 WO2011038069A1 (en) 2009-09-24 2010-09-23 Methods, compositions, and kits for reducing anti-antibody responses

Publications (2)

Publication Number Publication Date
AU2010298264A1 AU2010298264A1 (en) 2012-04-19
AU2010298264B2 true AU2010298264B2 (en) 2014-10-23

Family

ID=43756813

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010298264A Active AU2010298264B2 (en) 2009-09-24 2010-09-23 Methods, compositions, and kits for reducing anti-antibody responses

Country Status (8)

Country Link
US (6) US20110070230A1 (enExample)
EP (1) EP2480252A4 (enExample)
JP (1) JP2013505938A (enExample)
KR (1) KR20120093229A (enExample)
CN (1) CN102573895A (enExample)
AU (1) AU2010298264B2 (enExample)
CA (1) CA2775291A1 (enExample)
WO (1) WO2011038069A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) * 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US20110070230A1 (en) * 2009-09-24 2011-03-24 Xbiotech, Inc. Method and devices for identifying and treating a subject who has developed an anti-antibody response
WO2012151199A1 (en) * 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2012178173A1 (en) * 2011-06-24 2012-12-27 Centrose, Llc Extracellular targeted drug conjugates
US20130089496A1 (en) * 2011-10-07 2013-04-11 Musc Foundation For Research Development Tumor targeted antibodies and method for using the same
US10282875B2 (en) 2015-12-11 2019-05-07 International Business Machines Corporation Graph-based analysis for bio-signal event sensing
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030852A1 (en) * 1999-10-28 2001-05-03 Cambridge University Technical Services Limited Production of immunoglobulins which binds heterologous fcr with modified affinity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105245D0 (en) * 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
AU5152293A (en) * 1992-10-08 1994-05-09 Kennedy Institute Of Rheumatology, The Treatment of autoimmune and inflammatory disorders
GB9316989D0 (en) * 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US5856095A (en) * 1995-08-14 1999-01-05 St. Jude Children's Research Hospital Identification of two novel mutant alleles of human thiopurine S-methyltransferase, and diagnostic uses thereof
BRPI9707379C8 (pt) * 1996-02-09 2017-12-12 Abbott Biotech Ltd composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
US20020127625A1 (en) * 2000-03-31 2002-09-12 Forskarpatent Is Syd Ab Methods of diagnosing immune related diseases
WO2009117409A2 (en) * 2008-03-18 2009-09-24 Merck & Co., Inc. A high throughput protein interaction assay
US20110070230A1 (en) * 2009-09-24 2011-03-24 Xbiotech, Inc. Method and devices for identifying and treating a subject who has developed an anti-antibody response

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030852A1 (en) * 1999-10-28 2001-05-03 Cambridge University Technical Services Limited Production of immunoglobulins which binds heterologous fcr with modified affinity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GORMAN S. D., et al, "Humanisation of monoclonal antibodies for therapy", Seminars in Immunology, 1990, vol 2, no 6, pages 457-466 *
MAGDELAINE-BEUZELIN C., et al, "IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab", Pharmacogenetics and Genomics, May 2009, vol 19, pages 383-387 *

Also Published As

Publication number Publication date
EP2480252A1 (en) 2012-08-01
JP2013505938A (ja) 2013-02-21
CN102573895A (zh) 2012-07-11
AU2010298264A1 (en) 2012-04-19
US20110070230A1 (en) 2011-03-24
US20120094395A1 (en) 2012-04-19
US20110071054A1 (en) 2011-03-24
KR20120093229A (ko) 2012-08-22
US20120094301A1 (en) 2012-04-19
WO2011038069A1 (en) 2011-03-31
CA2775291A1 (en) 2011-03-31
US20110070229A1 (en) 2011-03-24
EP2480252A4 (en) 2014-04-30
US20110071276A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
AU2010298264B2 (en) Methods, compositions, and kits for reducing anti-antibody responses
Smith et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen
JP2009515827A (ja) 治療薬
Nielsen et al. Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5. 1/AS01B malaria vaccine
CN111153992A (zh) 结核分枝杆菌lam的单克隆抗体及其用途
CN116178529B (zh) 一株人源中和抗体或其抗原结合片段及其应用
Barrett et al. Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype
Reyes et al. Broadly inhibitory antibodies to severe malaria virulence proteins
CN116496394A (zh) 抗s100蛋白的抗体、检测s100蛋白的试剂和试剂盒
CN117088976B (zh) 一种抗nfl的单克隆抗体
CN112094346B (zh) 可应用于肿瘤细胞捕获的小鼠抗细胞单链跨膜糖蛋白cd142的单克隆抗体
CN112094352A (zh) 一种抗IgM单克隆抗体
CN117069840B (zh) 特异性检测il-21的抗体及应用
CN117050178B (zh) 特异性检测il-7的抗体及应用
WO2024201529A1 (en) Fully human monoclonal antibodies against chikungunya virus
CN120865418B (zh) 抗ror1抗体及其应用
CN120887991B (zh) 抗ror1抗体及其应用
CN118240067B (zh) 抗腺病毒抗体、检测腺病毒的试剂和试剂盒
US12188935B2 (en) Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs
CN115819568B (zh) 一种肠道病毒a71单克隆抗体及应用
CN118240068B (zh) 抗腺病毒抗体、检测腺病毒的试剂和试剂盒
Zhai et al. Monoclonal Antibody Development Technology for Important Human Diseases
US20210405026A1 (en) Method for evaluating the presence of a viral reservoir, and evaluating the efficacy of a drug against said reservoir
US20230061973A1 (en) Tat peptide binding proteins and uses thereof
JP2025514529A (ja) リンパ球の選択のための方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: XBIOTECH INC.

Free format text: FORMER NAME(S): XBIOTECH, INC.